News

Lilly, Roche plan Alzheimer’s blood screening in Korea

Health

Lilly, Roche plan Alzheimer’s blood screening in Korea

7 sourcesUpdated Oct 19, 20261 min read

0

Lilly, Roche plan Alzheimer’s blood screening in Korea — Photo: https://kaboompics.com/ / Wikimedia Commons (Pexels)

Sponsored

Eli Lilly and Roche Diagnostics Korea have agreed to promote blood-based biomarker testing as an early step in Alzheimer’s diagnosis, aiming to identify patients who may need confirmation through more costly amyloid PET scans or cerebrospinal fluid tests. Their partnership plans to support clinical adoption, clinician education and research into how well the tests work in Korean medical settings. The approach complements brain imaging: amyloid PET can confirm amyloid pathology and help guide decisions about anti-amyloid treatments, while tau PET may offer information about disease progression and prognosis.

Sponsored

In this story:Eli Lilly and CompanyHoffmann-La Roche

Where do you stand?

Eli Lilly and Company

Hoffmann-La Roche

More on this story

Back to News

Health

FDA Requires GLP-1 Warnings on Potential Blindness Risk

The FDA is requiring makers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to warn patients and clinicians about a possible risk of NAION, a rare condition caused by reduced blood flow to the optic nerve. The condition can cause sudden vision loss and, in severe cases, permanent blindness.

198 sources

Health

FDA approves first generic twice-yearly HIV-prevention shot

5

Total sources7

Last updatedOct 19, 2026

Does this breakdown look right?

Sponsored

How it spread

Broke Nature · Oct 16, 8:00 PM ETRight +32h7 sources +2d on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

FDA approved the first generic of twice-yearly HIV-prevention shot lenacapavir at about $40 a year for 120 resource-limited countries; U.S. brand lists at $28,218.

18 sources

Sponsored

Health

FDA grants uniQure Huntington’s gene therapy priority review

The FDA accepted uniQure’s application for priority review of its experimental Huntington’s disease gene therapy, setting a May 1, 2027, decision target and tentatively planning an advisory committee meeting. The application seeks accelerated approval based on clinical data compared with an external control; acceptance is not approval, and a confirmatory trial is planned.

8 sources